Stemedica Cell Technologies Email Format

BiotechnologyUnited States51-200 Employees

Stemedica Cell Technologies is a United States–based biotechnology research company focused on manufacturing clinical-grade stem cells, including ischemic-tolerant lines used in therapeutic applications. Its work targets medical researchers and clinicians seeking stem cell products for studies and potential treatments, addressing conditions related to ischemia through cellular therapies. The company operates within the biotechnology and regenerative medicine sector, positioning itself as a provider of specialized stem cell products for research and clinical use. Headquartered in the San Diego area, Stemedica has a workforce of professionals across a moderate-sized operation. In recent developments, the firm appointed Michael K. Steinhauser as Chief Executive Officer and Interim Chairman of the Board in May 2023, signaling leadership changes during a period of ongoing clinical exploration, including a phase 2b/3 trial for an intravenous allogenic mesenchymal stem cell treatment aimed at chronic ischemic stroke.

Get verified Stemedica Cell Technologies emails free

Company overview Employee directory